Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Morgan Advanced sales dip as expected, does not expect 'material' impact from tariffs

(Sharecast News) - Morgan Advanced Materials said on Thursday that first-quarter sales were lower as expected, but that it does not anticipate a material impact from tariffs. In an update ahead of its annual meeting, the company said sales in the first three months to 31 March fell 3.5% on an organic constant currency basis compared to the same period last year, as expected.

The maker of advanced carbon and ceramic materials said it continues to monitor and adapt its business to the recent introduction of new trade tariffs.

"With our predominantly localised manufacturing footprint the unmitigated direct impact of current tariffs is expected to be relatively small," it said. The group expects to be able to mitigate much of this and therefore does not expect a material net impact for the full year, "albeit that any broader economic impact remains uncertain".

Chief executive Pete Raby said: "Whilst the global economy is facing uncertainty in the short term, we remain confident in our strategy, and in the longer-term outlook for our products.

"Our decentralised organisation, cost management and strong balance sheet will provide us with the flexibility to navigate through this difficult period and deliver earnings growth with improving demand."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.